Peter H. O'Donnell to Response Evaluation Criteria in Solid Tumors
This is a "connection" page, showing publications Peter H. O'Donnell has written about Response Evaluation Criteria in Solid Tumors.
Connection Strength
0.156
-
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021 06; 22(6):872-882.
Score: 0.047
-
CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Rep (Hoboken). 2018 06; 1(1):e1002.
Score: 0.038
-
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017 Sep 14; 3(9):e172411.
Score: 0.037
-
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 07; 387(10031):1909-20.
Score: 0.033